INCR
InterCure Ltd.
There isn't enough reported data to score INCR yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
INCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Healthy |
INCR's balance sheet is currently healthy, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
INCR PE Valuation
INCR has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
INCR Forward outlook
There aren't enough analyst estimates for INCR to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
INCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.32 | -$0.18 |
| Q4 2023 | -$2.14 | -238% |
| Q4 2022 | $1.55 | +812% |
| Q4 2021 | $0.17 | +$2.61 |
| Q4 2020 | -$2.44 | -$2.25 |
| Q3 2020 | -$3.93 | -1059% |
| Q2 2020 | -$5.04 | -567% |
| Q1 2020 | -$5.75 | -459% |
NVO has the stronger earnings trend. Trailing diluted EPS is down 195% for INCR versus NVO up 4.9%.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
INCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $75M | -33% |
| Q4 2023 | $111.7M | -8.5% |
| Q4 2022 | $122.1M | +77% |
| Q4 2021 | $69M | +711% |
| Q4 2020 | $8.5M | +1382% |
| Q3 2020 | $7.1M | +766% |
| Q2 2020 | $3.5M | +303% |
| Q1 2020 | $1.3M | +147% |
INCR has the stronger quarterly revenue trend. Revenue is up 782% for INCR versus up 2.1% for NVO.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -28% | -56 points |
| Q4 2023 | -12% | -22 points |
| Q4 2022 | 13% | +21 points |
| Q4 2021 | 13% | +1125 points |
| Q4 2020 | 28% | +765 points |
| Q3 2020 | 11% | +566 points |
| Q2 2020 | -7.6% | +363 points |
| Q1 2020 | -1113% | -3300 points |
INCR's operating margin was −28% last quarter, down 56 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
INCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$22.4M | -$4.7M |
| Q4 2023 | -$17.7M | -278% |
| Q4 2022 | $9.9M | +187% |
| Q4 2021 | $3.5M | +136% |
| Q4 2020 | $1.5M | -84% |
| Q3 2020 | $525.2K | +$5.5M |
| Q2 2020 | -$2.9M | +$1.4M |
| Q1 2020 | -$3.1M | -$2.3M |
NVO has the stronger cash trend. Its trailing FCF is down 14% versus its history, compared with INCR at down 3,189%.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
INCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +59.3K shares |
| 1 year | +81% | +4.1M shares |
| 3 years | +138% | +5.3M shares |
| 5 years | +256% | +6.6M shares |
| Available history | +344% | +7.1M shares |
INCR has 9M diluted shares, up 81% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over INCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
INCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.1x | Net Cash |
| Q4 2021 | -3.2x | Net Cash |
| Q4 2020 | -3.7x | Net Cash |
| Q3 2019 | -0.4x | Net Cash |
| Q2 2019 | -2.1x | Net Cash |
| Q1 2019 | 0.3x | Very low |
| Q4 2016 | -0.4x | Net Cash |
INCR has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
INCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 13.5 | Oversold |
INCR's weekly RSI is 42 (neutral) and its Stochastic is 14 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
INCR PE vs Healthcare Sector
| Metric | INCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INCR has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
INCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 12% below |
| 20 week MA | $4.83 | 18% below |
| 50 week MA | $4.77 | 17% below |
| 100 week MA | $6.21 | 36% below |
| 200 week MA | $8.06 | 51% below |
INCR is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over INCR on trend strength, trading above more of its moving averages.
INCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.45 | $6.00 | +10% |
| 2021 | $6.00 | $36.0 | +500% |
| 2022 | $36.0 | $19.2 | -47% |
| 2023 | $19.2 | $6.45 | -66% |
| 2024 | $6.45 | $8.15 | +26% |
| 2025 | $8.15 | $5.65 | -31% |
| 2026 YTD | $5.65 | $3.98 | -30% |
INCR's yearly returns have swung widely, from +500% in 2021 to −66% in 2023. It's down 30% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over INCR on returns for 2026, with the stronger performance.